Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia

Br J Haematol. 2019 Oct;187(2):e45-e48. doi: 10.1111/bjh.16166. Epub 2019 Aug 22.
No abstract available

Keywords: TP53; acute myeloid leukaemia; decitabine; hypomethylating agents; venetoclax.

Publication types

  • Clinical Trial
  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Bridged Bicyclo Compounds, Heterocyclic / administration & dosage*
  • Female
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / genetics*
  • Male
  • Middle Aged
  • Mutation*
  • Retrospective Studies
  • Sulfonamides / administration & dosage*
  • Tumor Suppressor Protein p53 / genetics*

Substances

  • Bridged Bicyclo Compounds, Heterocyclic
  • Sulfonamides
  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • venetoclax